[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"National Heart Centre Singapore\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":351},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,41,62,88,108,141,162,182,206,224,251,274,300,330],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100612873","singapore-sonicracker-intravascular-lithotripsy-sing-ivl-study-100612873",false,"NCT07259239","SINGapore SoniCracker IntraVascular Lithotripsy (SING IVL) Study","Inclusion Criteria:\n\n1. Patients at age ≥ 21 years old.\n2. Patients undergoing elective\u002F planned PCI with at least moderate coronary calcification on angiography at the target lesion are eligible for enrolment. Moderate coronary calcification is defined as densities on only one side of the arterial wall prior to contrast injection. Severe calcification was defined as radiopacities on both sides of the arterial wall prior to contrast injection.\n3. Patients need to demonstrate evidence of either a 180 arc of coronary calcium or nodular calcium at the target lesion on intravascular imaging prior to IVL therapy.\n\nExclusion Criteria:\n\n1. Significant co-morbidities:\n\n   * Cardiac arrest\n   * Cardiogenic shock\n   * Collapse \u002F comatose \u002F semi-conscious states\n2. Patients requiring urgent or emergent PCI.\n3. Patients who are unable to provide consent.\n4. Patients who are pregnant.\n5. Breast-feeding women\n6. Any patients whom the Investigator deems unsuitable for the study (e.g., due to other medical reasons, laboratory abnormalities, expected study medication noncompliance, or subject's unwillingness to comply with all study-related study procedures).","ALL","21 Years",{"count":18,"type":19},40,"ESTIMATED","INTERVENTIONAL",[22],"NA","Interventional cardiologists are facing an increasing burden of calcified coronary arteries in keeping with an ageing population and rising prevalence of diabetes mellitus and chronic kidney disease. Heavily calcified plaques impede balloon dilatation and successful stent delivery, resulting stent under-expansion, malposition, and damage to the drug-eluting polymer coats. This translates to poorer procedural outcomes and increased risk of Major Adverse Cardiovascular Events (MACE). The investigators' proposal seeks to determine the feasibility of the SoniCracker IVL in patients with calcified coronary lesions.",[25],"Cardiovascular Diseases",[27],"SING-IVL","RECRUITING","2025-11-26",{"date":31,"type":32},"2025-12-02","ACTUAL",{"date":34,"type":32},"2025-09-30",{"date":36,"type":19},"2026-07",{"name":38,"class":39},"National Heart Centre Singapore","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},"100597472","the-asia-pacific-mitral--tricuspid-valve-in-valvevalve-in-ring-registry-ap-viv-registry-100597472","NCT07058935","The Asia-Pacific Mitral & Tricuspid Valve-in-Valve\u002FValve-in-Ring Registry (AP ViV Registry)","Inclusion Criteria:\n\n1. Age ≥ 21\n2. Had at least one documented Mitral valve-in-valve\u002Fvalve-in-ring procedure done during the period of 1 Jan 2023 to current date. (Retrospective) OR Planned to undergo a Mitral valve-in-valve\u002Fvalve-in-ring procedure. (Prospective) OR Had at least one documented Tricuspid valve-in-valve\u002Fvalve-in-ring procedure done during the period of 1 Jan 2023 to current date. (Retrospective) OR Planned to undergo a Tricuspid valve-in-valve\u002Fvalve-in-ring procedure. (Prospective)\n\nExclusion Criteria:\n\n1. Active endocarditis\n2. Any other conditions which investigator deems unsuitable for participation.",{"count":48,"type":19},150,"OBSERVATIONAL","A retrospective and prospective, observational, multicenter cohort study of consecutive patients undergoing transcatheter mitral\u002Ftricuspid ViV or ViR procedure with balloon expandable valve across participating sites in Asia-Pacific.",[52],"Valve Disease, Heart","2025-07-01",{"date":55,"type":32},"2025-07-10",{"date":57,"type":32},"2025-03-17",{"date":59,"type":19},"2035-12",{"name":38,"class":39},8,{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":69,"enrollmentInfo":70,"targetDuration":4,"studyType":20,"phases":72,"briefSummary":73,"conditions":74,"keywords":75,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},"100511955","tackling-disruptions-to-frailty-interventions-developing-personalized-interventions-targeted-for-older-persons-with-cardiac-frailty-100511955","NCT05946174","Tackling Disruptions to Frailty Interventions: Developing Personalized Interventions Targeted for Older Persons With Cardiac Frailty","INDEPENDENCY","Inclusion Criteria:\n\n* Age ≥ 21 years old\n* Outdoor ambulant\n\nExclusion Criteria:\n\n1. Bed-bound\n2. Dementia (Stage 6 onwards)\n3. Residing in sheltered or nursing home\n4. Cancer (to avoid confounding with cardiac disease sequelae from cancer)\n5. Participation in ongoing clinical trials that involve interventional drugs or devices\n6. Uncontrolled hypertension (systolic blood pressure ≥160mmHg and\u002For diastolic blood pressure ≥90mmHg) despite being on treatment for hypertension\n7. Low blood pressure (systolic blood pressure \\\u003C90mmHg or diastolic blood pressure \\\u003C40mmHg)\n8. Uncontrolled atrial fibrillation (controlled atrial fibrillation is allowed)\n9. Ventricular arrhythmias (such as ventricular tachycardia)\n10. Renal failure on dialysis\n11. Chronic kidney disease Stage 4 and above\n12. Nephrotic syndrome\n13. Liver cirrhosis Child's B and above\n14. Inflammatory Bowel Disease\n15. Severe uncontrolled gout\n16. Poorly controlled Diabetes Hba1c ≥9%\n17. On warfarin\n18. Presence of food allergies (such as shell-fish, prawn)\n19. Patient's life expectancy is expected to be less than one year at the time of potential enrolment as assessed by the investigator\n20. Nasogastric or parenteral nutrition\n21. Hypertrophic cardiomyopathy\n22. Cardiac amyloidosis\n23. Cardiac sarcoidosis","100 Years",{"count":71,"type":19},500,[22],"Background: Muscle mass loss and metabolic dysfunction, exacerbated by inactivity and nutritional inadequacies, underpin both cardiovascular disease and frailty in ageing. The investigators' proposal seeks to develop interventions in exercise and diet that are targeted for older adults with cardiac frailty.\n\nMethods:\n\nThe investigators' proposal is a five-year study comprising of first phase (first 2-2.5 years) and second phase (next 2-2.5 years). In the first phase cardiac frail participants (up to N=500) from each healthcare transition (inpatient hospital, step-down community hospital, outpatient clinic\u002Fcommunity) will be randomized to receive Intervention Sets or usual care. The second phase will scale up these programs. Three Intervention Sets A, B, and C will be implemented in the outpatient, step-down community hospital, and acute hospital settings. Diet intervention comprises meal sets prepared with nutrients involved in energy metabolism. Exercise training is facilitated by hospital gyms and hospital physiotherapists. Diet and exercise behavior will be monitored using questionnaires, video conferencing and meal photos.\n\nSignificance: Clinical studies are urgently needed using consistent frailty tools to evaluate the efficacy and promise of frailty interventions, targeted to achieve reversal\u002Fretardation of frailty. When scaled up, these approaches will provide high-quality science needed to manage cardiac frailty towards healthier population ageing.",[25],[76,77,78],"Frailty","Intervention","Cardiac Frailty Interventions","2025-06-03",{"date":81,"type":32},"2025-06-05",{"date":83,"type":32},"2023-07-12",{"date":85,"type":19},"2028-06-21",{"name":38,"class":39},6,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":94,"sex":15,"minAge":16,"maxAge":69,"enrollmentInfo":95,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":102,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":40},"100498840","exercise-to-slow-cardiovascular-ageing-progression-100498840","NCT05775484","Exercise to Slow Cardiovascular Ageing Progression","Inclusion Criteria:\n\n* Age \\>=21 years old\n* Outdoor ambulant\n\nExclusion Criteria:\n\n* Wheelchair or bed-bound\n* Dementia\n* Residing in sheltered or nursing home\n* Cancer\n* Participation in ongoing clinical trials that involve interventional drugs or devices\n* Aneurysms\n* Acute infections (in the last six months)\n* Uncontrolled thyrotoxicosis\n* Neuromuscular, musculoskeletal or rheumatoid disorders that are exacerbated by exercise\n* Uncontrolled asthma or chronic lung disease\n* Restrictive lung disease",true,{"count":96,"type":19},450,"In ageing, deleterious alterations in cardiovascular (CV) structure and function increase risks of ageing-related cardiovascular disease (CVD). Investigators found that these CV alterations were associated with circulating serum metabolites, suggesting a metabolic basis to CV ageing. Investigators hypothesize that modification of these metabolites by intervention, such as exercise, may retard CV alterations and reduce CVD in ageing.",[99,100,101],"Cardiac Ageing","Exercise","Cardiovascular",{"date":81,"type":32},{"date":104,"type":32},"2023-05-01",{"date":106,"type":19},"2050-12-31",{"name":38,"class":39},{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":94,"sex":15,"minAge":16,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":20,"phases":118,"briefSummary":120,"conditions":121,"keywords":126,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":40},"100565708","phase-2-hyperpolarized-mr-imaging-with-carbon-13-pyruvate-in-the-human-body-100565708","NCT06645691","Hyperpolarized MR Imaging with Carbon-13 Pyruvate in the Human Body","POLARIC-13","Inclusion Criteria:\n\nHealthy Volunteers:\n\n1. Age 21 years and above\n2. No significant medical co-morbidities (such as chronic kidney disease, diabetes mellitus, heart failure, ischemic heart disease, previous strokes)\n3. No history of cancer\n4. Able and willing to comply with study procedures and provide signed informed consent\n\nPatients with cardiovascular\u002Fcardiometabolic diseases:\n\n1. Age 21 years and above\n2. Physician diagnosed cardiovascular conditions: ischemic heart disease, inherited cardiomyopathies (hypertrophic, dilated or infiltrative cardiomyopathies) and stable heart failure; and\u002For\n3. Cardiometabolic conditions (such as diabetes on medications, hypertension, central obesity, fatty liver disease)\n4. Able and willing to comply with study procedures and provide signed informed consent\n\nExclusion Criteria:\n\n1. Standard contraindications for magnetic resonance procedures (such as implantable medical devices, suspected presence of surgical apparatus or shrapnel, severe claustrophobia)\n2. Unstable medical conditions (such as symptomatic heart failure, unstable hypertension\u002Fglucose levels as determined by investigators, symptomatic arrhythmias, angina)\n3. Pregnant or nursing women\n4. Known allergies to pyruvate or any of its components","99 Years",{"count":117,"type":19},200,[119],"PHASE2","Positron emission tomography with 18F fluorodeoxyglucose (FDG) is the conventional imaging technique to provide information regarding tissue glucose uptake and has been highly clinically successful. However, it cannot assess downstream metabolism, which may be useful in the diagnosis and assessment of treatment response in a variety of diseases. Patients will also be exposed to ionizing radiation, the amount of exposure can vary depending on the dose of tracer administered, frequency of scans and duration of each scan. Carbon-13 (13C) magnetic resonance imaging (MRI) is particularly attractive for metabolic imaging because carbon serves as the backbone of nearly all organic molecules in the body. With this technique, the polarization increases to approximately 30%-40%, an increase of over 10,000 to 100,000-fold, thereby dramatically increasing the MRI signal . Whilst the role of 13C imaging has been demonstrated in many sites around the world, we aim to demonstrate the feasibility and application of 13C hyperpolarized imaging in healthy Singapore residents and patients with cardiovascular and\u002For cardiometabolic diseases.",[122,123,124,25,125],"Heart Failure","Cardiometabolic Syndrome","Cancer Diagnosis","Healthy Volunteers",[127,128,129,130,131,132],"Carbon-13 Pyruvate","Magnetic Resonance Imaging","Lactate","Alanine","Bicarbonate","Hyperpolarized Pyruvate (13C) Injection","2024-12-03",{"date":135,"type":32},"2024-12-06",{"date":137,"type":32},"2024-10-17",{"date":139,"type":19},"2028-05-31",{"name":38,"class":39},{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":151,"conditions":152,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":40},"100569753","understanding-novel-variants-in-acute-myocardial-infarction-in-young-adults-100569753","NCT06698341","UNdeRstAnding Novel Variants in AcutE MyocardiaL Infarction in Young Adults","UNRAVEL","Inclusion Criteria:\n\n1. Adult \\>21 years old.\n2. Age ≤50 years old irrespective of the presence of CV risk factors\\* at the time of myocardial infarction OR Age 51-60 years old with no more than 2 CV risk factor\\* at the time of myocardial infarction, excluding diabetes mellitus\n3. Able to provide informed consent.\n4. Patients who are willing and able to comply with the study visit and procedures.\n5. Prior type 1 myocardial infarction with angiographically\u002FCT documented significant stenosis of ≥50% in LM or ≥70% in major epicardial\u002Fbranch vessel (e.g. LAD, LCX, RCA).\n6. Patients who are from the three main races (Chinese, Malay, Indian). Race is self-identified by patient.\n\n   * Hypertension, hyperlipidemia, diabetes mellitus, obesity, current smoker\n\nExclusion Criteria:\n\n1. Known familial hypercholesterolaemia, known vasculitides, end-stage renal disease and congenital heart disease.\n2. Prior PAD and Stroke\n3. Female patients who are pregnant\n4. Patients who are non-Asian","60 Years",{"count":150,"type":19},1200,"Cardiovascular disease (CVD) imposes significant mortality and morbidity worldwide. However, large gaps in our knowledge of CVD still exist. The clinical conundrum of the extremes of spectrums of CVD continues to baffle clinicians and researchers alike. These include patients without any major cardiovascular (CV) risk factors developing acute myocardial infarction (AMI) at a relatively young age (\\\u003C50-60 years old), while at the other end of the spectrum, there are also patients with multiple CV risk factors but with minor or no coronary artery disease. These suggest the presence of other factors that predispose these patients to AMI.Recent advancements in technology, especially in the field of genomics, metabolomics, and proteomics, have led to exciting developments in our understanding of the development and prevention of CVD and AMI. In this study, the investigators aim to identify novel gene variants associated with the onset of MI in relatively young patients with minimal standard CV risk factors such as diabetes, obesity, hypertension and hypercholesterolaemia.Through genomic, metabolomics and proteomics analyses, this may better improve our understanding of the development of CVD and AMI, potentially developing novel preventive measures to reduce the risk or delay the onset as well as tailoring management plans to improve treatment outcomes and reduce adverse events for the patients.",[153],"Myocardial Infarction, Acute","2024-11-18",{"date":156,"type":32},"2024-11-21",{"date":158,"type":32},"2024-04-29",{"date":160,"type":19},"2028-04",{"name":38,"class":39},{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":115,"enrollmentInfo":169,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":40},"100498837","extremes-of-coronary-artery-disease-and-normalitycad-extremes-100498837","NCT05775445","Extremes of Coronary Artery Disease and Normality:CAD Extremes","Extremes of Coronary Artery Disease and Normality: Understanding Novel Causative and Protective Factors in the Development of Coronary Artery Disease (CAD Extremes)","Inclusion Criteria:\n\nGroup 1:\n\n1. Evidence of significant CAD a. Coronary angiogram or CT coronary angiogram with documented stenosis \\>=50% in left main or \\>=70% in major epicardial vessel or major branches (LAD, LCX, RCA)\n\n   AND all of the following\n2. Age \\\u003C\u002F= 45 for males and \\\u003C\u002F= 50 for females\n3. Absence of diabetes mellitus\n4. Absence of tobacco use\n5. No prior CVA or PAD\n\nGroup 2\n\n1. Evidence of significant CAD\n\n   1. Coronary angiogram or CT coronary angiogram with documented stenosis \\>=50% in left main or \\>=70% in major epicardial vessel or major branches (LAD, LCX, RCA)\n\n   AND all of the following\n2. Age \\\u003C\u002F= 45 for males and \\\u003C\u002F= 50 for females\n3. Absence of diabetes mellitus\n4. Absence of tobacco use\n5. No prior CVA or PAD\n\nGroup 3 1. Evidence of significant CAD with one of the following:\n\n1. age\\>65\n2. Diabetes mellitus\n3. End Stage Renal Failure (ESRF)\n4. Framingham risk score \\>10%\n\nGroup 4\n\n1\\. No evidence of significant CAD and all of the following\n\n1. Age \\\u003C55 for males, \\\u003C65 for females\n2. Absence of diabetes mellitus\n3. Absence of CKD\n4. Absence of tobacco use\n\nExclusion Criteria:\n\n1. Prior history of cancer (excludes pre-cancerous lesions)\n2. Expected life expectancy less than 1 year\n3. Known autoimmune disease\n4. Psychiatric illness\n5. Chronic lung disease requiring long term medications or oxygen\n6. Chronic infective disease, including tuberculosis, hepatitis B and C; and HIV\n7. Inability to comply with study protocol\n8. Any other acute or chronic medical or physical condition deemed by the investigator to affect study outcomes",{"count":170,"type":19},1500,"In the field of cardiovascular medicine, there are two differing groups of patients that remain puzzling to clinicians: patients who are not expected to have coronary artery disease (CAD) yet are diagnosed with significant CAD; and those who are have multiple risk factors for CAD but do not have CAD. Bats exhibit unique phenotypes including long lifespans and likely reduced atherosclerosis. Prior work has identified multiple molecular mechanisms of suppressing the activation of inflammasomes, causally linked to atherosclerosis. The investigators hypothesize there are different molecular markers that confer protection or increased risk for CAD, some of which may be similar to bats. Thus, the aim of this study is to identify molecular markers that contribute to or are protective against acute coronary syndrome (ACS) through analyzing the genetics, peripheral blood and atherosclerotic samples from both extreme patient groups using single-cell RNA sequencing and multi-omics approach. In addition, novel anti-atherosclerotic mechanisms and factors from bat studies will be assessed in the human samples. Identification of novel targets that prevent or cause CAD has the potential to aid in the early identification of high-risk patients and development of new therapeutics to combat this growing epidemic. To conduct this study, patients who have undergone a coronary angiogram or a CT coronary angiogram that fall into the both extremes will be recruited and blood samples will be taken for the above analysis. These will be compared to a group of controls (low risk without disease and high risk with disease).",[173],"Coronary Artery Disease","2024-02-19",{"date":176,"type":32},"2024-02-21",{"date":178,"type":32},"2023-05-30",{"date":180,"type":19},"2027-12",{"name":38,"class":39},{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":94,"sex":15,"minAge":16,"maxAge":115,"enrollmentInfo":188,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":190,"conditions":191,"keywords":195,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":40},"100260482","response-of-the-myocardium-to-hypertrophic-conditions-in-the-adult-population-100260482","NCT02670031","Response of the Myocardium to Hypertrophic Conditions in the Adult Population","Inclusion Criteria:\n\n1. 21 years and over\n2. Physician diagnosed essential hypertension, on at least 1 medication for blood pressure control\n3. Newly diagnosed hypertension: systolic blood pressure 140mmHg or greater (diastolic blood pressure 90mmHg or greater) on at least 2 office visits (Weber 2013) and not started on any anti hypertensive medications at time of ambulatory blood pressure monitoring\n4. Resistant hypertension: persistent systolic blood pressure 140mmHg or greater (diastolic blood pressure 90mmHg or greater) despite on at least 3 anti-hypertensive medications (Jennings 2013; Weber 2013)\n\nExclusion Criteria:\n\n1. Known secondary hypertension: renal causes (renal artery stenosis, chronic renal failure); endocrine causes (aldosterone excess, pheochromocytoma, cushing's syndrome, hyperthyroidism); cardiac causes (coarctation of the aorta)\n2. Contraindications to cardiovascular magnetic resonance: implantable devices, cerebral aneurysm clips, cochlear implants, renal impairment (GRF \\\u003C30ml\u002Fmin\u002F1.73m2), claustrophobia and women who are pregnant or breast-feeding\n3. Limited life expectancy\n4. On-going unstable medical conditions: hypertensive crisis, acute coronary syndromes or acute heart failure\n5. History of coronary artery disease, ischemic heart disease\n6. History of transient ischemic attacks or cerebrovascular events\n7. History of atrial fibrillation\n8. History of heart failure",{"count":189,"type":19},2000,"Hypertension and aortic stenosis are the two leading conditions that cause thickening of the heart muscles (left ventricular hypertrophy). Left ventricular hypertrophy is initially adaptive to maintain optimal heart function. Ultimately, heart failure occurs as a result of progressive muscle cell death and scarring (myocardial fibrosis). Dedicated techniques using cardiovascular magnetic resonance imaging (MRI) and novel high-sensitivity cardiac troponin blood assays are potential markers to detect myocardial fibrosis. Although hypertension-related heart disease is very common in Singapore, the significance of myocardial fibrosis is not well understood. In this study, the significance of myocardial fibrosis in 2000 patients with hypertension would be investigated. This will be the largest study using state-of-the-art MRI to examine the importance of myocardial fibrosis in hypertensive heart disease. 1000 participants, with at least 1 year follow-up, will be invited for a repeat assessment.",[192,193,194],"Left Ventricular Hypertrophy","Hypertension","Myocardial Fibrosis",[196,193,192,194,197],"Hypertensive Heart Disease","Cardiovascular Magnetic Resonance Imaging","2023-07-31",{"date":200,"type":32},"2023-08-02",{"date":202,"type":4},"2016-01",{"date":204,"type":19},"2031-09",{"name":38,"class":39},{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":115,"enrollmentInfo":212,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":213,"conditions":214,"keywords":4,"overallStatus":215,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":40},"100487394","jarvisdhl-screening-tools-100487394","NCT05626517","JARVISDHL Screening Tools","Inclusion Criteria for NHCS:\n\n1. 21 years of age or older\n2. Sufficient language skills in English or Chinese\n3. Provided informed consent\n4. Completed CTCA or CT CAC in the past 6 months.\n\nInclusion Criteria for SERI:\n\n1. 21 years of age or older\n2. Sufficient language skills in English or Chinese\n3. Provided informed consent\n4. Patient diagnosed with Diabetes for more than or equal to 10 years.\n\nExclusion Criteria for NHCS:\n\n1. Patients whose informed consent was not obtained.\n2. Age \\\u003C21 years old\n3. Patients with cardiac event (acute myocardial infarction, Stroke, heart failure, angina requiring hospitalization) and\u002For coronary revascularization (percutaneous coronary intervention (PCI) and\u002For coronary artery bypass grafting (CABG) prior to CTCA\n\nExclusion Criteria in SERI:-\n\n1. Patient whose informed consent was not obtained.\n2. Age \\\u003C21 years old\n3. Patients with cardiac event (acute myocardial infarction, Stroke, heart failure, angina requiring hospitalization) and\u002For coronary revascularization (percutaneous coronary intervention (PCI) and\u002For coronary artery bypass grafting (CABG) prior to CTCA",{"count":189,"type":19},"The main purpose of this study is to pioneer an easy risk stratification tools, which is developed using novel artificial intelligence (AI) algorithms, that will be able to detect common and fatal heart diseases easily simply through a picture of the back of the eye, the retina. The retinal images will be analysed using a computer application with the risk stratification tool to predict health outcome of individual. The study also aims to correlate between clinical characteristics, lifestyle (eg. exercise, sleep, erectile dysfunction) and diet to retinal and coronary vasculature and clinical outcomes.",[173],"NOT_YET_RECRUITING","2022-11-22",{"date":218,"type":32},"2022-11-23",{"date":220,"type":19},"2023-01-30",{"date":222,"type":19},"2027-06-30",{"name":38,"class":39},{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":232,"enrollmentInfo":233,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":235,"conditions":236,"keywords":240,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":249,"locationsCount":250},"100478364","ai-driven-national-platform-for-ct-coronary-angiography-for-clinical-and-industrial-applications-registry-100478364","NCT05509010","AI Driven National Platform for CT cOronary Angiography for clinicaL and industriaL applicatiOns Registry","AI Driven National Platform for CT cOronary Angiography for clinicaL and industriaL applicatiOns Registry (APOLLO)","APOLLO","Inclusion Criteria:\n\n1. Age ≥21 years old\n2. Signed informed consent\n3. Clinically indicated for evaluation by CTCA\n\nExclusion Criteria:\n\n1. Individuals unable to provide informed consent\n2. Known complex congenital heart disease\n3. Planned invasive angiography for reasons other than CAD\n4. Non-cardiac illness with life expectancy \\\u003C 2 years\n5. Pregnancy\n6. Concomitant participation in another clinical trial in which subject is subject to investigational drug or device\n7. Cardiac event and\u002For coronary revascularization (percutaneous coronary intervention (PCI) and\u002For coronary artery bypass grafting (CABG) and\u002For valvular repair\u002Freplacement prior to CTCA\n8. Glomerular Filtration Rate ≤ 30mL\u002Fmin\n9. Known allergy to iodinated contrast agent\n10. Contraindications to beta blockers or nitroglycerin or adenosine","80 Years",{"count":234,"type":19},8000,"The overall aim is to build an AI driven national Platform for CT cOronary angiography for clinicaL and industriaL applicatiOns (APOLLO) for automated anonymization, reporting, Agatston scoring and plaque quantification in CAD. It is a \"one-stop\" platform spanning diagnosis to clinical management and prognosis, and aid in predicting pharmacotherapy response.",[237,173,238,239],"CAD","Coronary Stenosis","Plaques; Epicardial",[241,242],"CTCA","CT Coronary Angiography","2022-08-18",{"date":245,"type":32},"2022-08-19",{"date":247,"type":32},"2021-10-01",{"date":180,"type":19},{"name":38,"class":39},3,{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":11,"sex":15,"minAge":258,"maxAge":4,"enrollmentInfo":259,"targetDuration":4,"studyType":20,"phases":261,"briefSummary":263,"conditions":264,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":40},"100384492","phase-4-asian-diabetes-outcomes-prevention-trial-100384492","NCT04286399","Asian Diabetes Outcomes Prevention Trial","ADOPT","Inclusion Criteria:\n\n* Type 2 diabetes for at least six months\n* ≥ 40 years of age, men or women\n* No known cardiovascular disease ( defined as known coronary stenosis \\> 70%, reduced left ventricular ejection fraction \\\u003C 40%, or a history of myocardial infarction\u002F coronary revascularization\u002F heart failure hospitalization\u002F stroke\u002F prior non-traumatic lower limb amputation or angioplasty)\n* NT-proBNP \\> 125 pg\u002FmL\n* Written informed consent\n\nExclusion Criteria:\n\n* History of hypersensitivity to any of the drugs investigated as well as known or suspected contraindications to the study drugs or previous history of intolerance\n* Patients already on a maximum dose of RAASi or beta-blocker\n* History of DM ketoacidosis\u002FType 1 DM\n* eGFR \\\u003C 45ml\u002Fmin\u002F1.73m2\n* Symptomatic hypotension and\u002For Visit 1 systolic blood pressure (SBP) \\\u003C 100mmHg.\n* Symptomatic bradycardia, high-grade AV blocks (Grade 2 and 3) and\u002For Visit 1 heart rate (HR) \\\u003C 60bpm.\n* Any disease other than diabetes lowering the patient's life expectancy to less than two years.\n* Chronic infections (E.g. chronic cystitis, recurrent urinary tract infections) or malignancies or uncontrolled thyroid disorder or liver disease\n* Systemic treatment with corticosteroids.\n* Pregnant or nursing women\n* Any other clinical condition that might affect patients' safety during trial, at the investigator's discretion.\n* Participation in an investigational drug trial","40 Years",{"count":260,"type":19},2400,[262],"PHASE4","The aim of this study is to identify patients with DM at high risk of CVD using elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels (\\>125pg\u002FmL), and (2) intensify therapy using renin-angiotensin system (RAS) antagonists, beta-blockers and sodium glucose co-transporter-2 inhibitors (SGLT2i) for primary prevention of cardiovascular events in this high-risk DM population.",[265,25],"Diabetes Mellitus","2021-04-28",{"date":268,"type":32},"2021-04-30",{"date":270,"type":32},"2019-07-01",{"date":272,"type":19},"2034-06-30",{"name":38,"class":39},{"id":275,"slug":276,"hasResults":11,"nctId":277,"briefTitle":278,"officialTitle":278,"acronym":279,"eligibilityCriteria":280,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":281,"targetDuration":283,"studyType":49,"phases":4,"briefSummary":284,"conditions":285,"keywords":287,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":299},"100419496","rovus-asia-registry-evaluate-safety-and-effectiveness-of-rotational-atherectomy-and-intravascular-ultrasound-for-heavily-calcified-coronary-lesion-100419496","NCT04742478","ROVUS Asia Registry (Evaluate Safety and Effectiveness of Rotational Atherectomy and Intravascular Ultrasound for Heavily Calcified Coronary Lesion)","ROVUS","Inclusion Criteria:\n\n* Able to understand and sign an informed consent form\n* Presence of clinical indication for percutaneous coronary intervention (PCI) and\u002For stent placement\n* Subjects willing to comply with all research and follow-up requirements.\n* Angiographic criteria (ONE of the following criteria MUST be met)\n\n  1. Target lesions visually have at least moderate calcifications\\*\n  2. Target lesion balloon dilatation failure\n  3. Inability of devices (microcatheters, balloons or stents) to pass through the target lesion.\n* Procedural criteria\n\n  1. All patients treated with RA with or without other forms of debulking therapy\n\n     * Moderate calcification is defined as radio-opacities noted only during cardiac cycle prior to contrast injection whereas severe calcification is defined as radio-opacities seen without cardiac motion prior to contrast injection, usually affecting both sides of the arterial lumen.\n\nExclusion Criteria:\n\n* Decline to give consent",{"count":282,"type":19},1000,"1 Year","Rotablation with or without other calcium debulking therapies is a safe adjunctive procedure for patients with severe coronary calcification requiring Percutaneous Coronary Intervention (PCI).",[286],"Coronary Artery Calcification",[288,289,290],"Atherosclerotic Calcification","Medial Artery Calcification","Rotational Atherectomy","2021-04-21",{"date":293,"type":32},"2021-04-23",{"date":295,"type":32},"2021-03-10",{"date":297,"type":19},"2026-12-31",{"name":38,"class":39},2,{"id":301,"slug":302,"hasResults":11,"nctId":303,"briefTitle":304,"officialTitle":304,"acronym":305,"eligibilityCriteria":306,"healthyVolunteers":94,"sex":15,"minAge":307,"maxAge":308,"enrollmentInfo":309,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":311,"conditions":312,"keywords":317,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":40},"100270765","molecular-and-imaging-studies-of-cardiovascular-health-and-disease-100270765","NCT02804269","Molecular and Imaging Studies of Cardiovascular Health and Disease","Biobank","There is no inclusion\u002Fexclusion criteria except for the age limit as this is a repository program.\n\nInclusion Criteria:\n\n•Subject aged ≥ 16 years and ≤ 90 years.\n\nExclusion Criteria:\n\n•No","16 Years","90 Years",{"count":310,"type":19},5000,"Biobank is a program which collects biological samples, health information and imaging data from consented patients and stored them at the core facility. These information would be used to study the molecular, imaging and outcome studies of cardiovascular health and disease.",[313,314,315,316],"Healthy","Dilated Cardiomyopathy","Hypertrophic Cardiomyopathy","Ischemic Heart Disease",[318,319,320,321,197],"Healthy Volunteer","Dilated cardiomyopathy","Hypertrophic cardiomyopathy","ischemic heart disease","2016-06-14",{"date":324,"type":19},"2016-06-17",{"date":326,"type":4},"2013-07",{"date":328,"type":19},"2033-07",{"name":38,"class":39},{"id":331,"slug":332,"hasResults":11,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":336,"eligibilityCriteria":337,"healthyVolunteers":94,"sex":15,"minAge":16,"maxAge":338,"enrollmentInfo":339,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":340,"conditions":341,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":40},"100269761","effects-of-physical-activity-ambulatory-blood-pressure-and-calcium-score-on-cardiovascular-health-in-normal-people-100269761","NCT02791152","Effects of Physical Activity, Ambulatory Blood Pressure and Calcium Score on Cardiovascular Health in Normal People","SingHEART: Effects of Physical Activity, Ambulatory Blood Pressure and Calcium Score on Cardiovascular Health in Normal People","SingHEART","Inclusion Criteria:\n\n* Men and women age 21-69 years\n\nExclusion Criteria:\n\n1. Previous myocardial infarction (MI). This will include ST-elevation MI (STEMI) and non-ST-elevation MI (NSTEMI)\n2. Known coronary artery disease - prior coronary revascularization\n3. Known documented peripheral arterial disease\n4. Previous stroke\n\n   a. Stroke is defined as new focal neurological deficit persisting more than 24hours21.\n5. More than ongoing use of 2 or more anti-hypertensive agents\n6. Prior history of cancer (excludes pre-cancerous lesions)\n7. Expected life expectancy less than 1 year\n8. Known definite diabetes mellitus or on treatment for diabetes mellitus\n9. Known autoimmune disease or genetic disease\n10. Known endocrine disease on treatment\n11. Psychiatric illness\n12. Asthma or chronic lung disease requiring long term medications or oxygen\n13. Chronic infective disease, including tuberculosis, hepatitis B and C; and HIV\n14. Inability to comply with study protocol\n15. Any other acute or chronic medical or physical condition deemed by the investigator to affect study outcomes","69 Years",{"count":282,"type":19},"A prospective cohort of relatively healthy individuals, using comprehensive clinical information, advanced imaging (including cardiac MRI), cardiovascular exercise physiology, metabolomics and genetic analysis. These findings will be correlated with adverse clinical outcomes including death, stroke and myocardial infarction. In selected cases, follow-up imaging and biomarker samples will also be obtained. These studies will enable us to begin to address a critical gap in our knowledge as to how best to interpret the very large amount of cardiovascular tests done in Singapore and how to better to predict outcomes and manage healthcare costs in our local populations",[342],"Myocardial Infarction","2016-05-31",{"date":345,"type":19},"2016-06-06",{"date":347,"type":4},"2015-10",{"date":349,"type":19},"2036-12",{"name":38,"class":39},""]